Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capecitabine + nab-paclitaxel
- Development stage
- Phase 3
- Lead developer
- GBG Forschungs
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Oral
01
Overview
Capecitabine + nab-paclitaxel is a combination chemotherapy regimen investigated by the German Breast Group (GBG Forschungs GmbH) for the adjuvant treatment of early breast cancer in elderly patients. The regimen consists of nab-paclitaxel, an albumin-bound nanoparticle formulation of paclitaxel, and capecitabine, an oral fluoropyrimidine carbamate. Nab-paclitaxel functions as a microtubule inhibitor by promoting the assembly of microtubules from tubulin dimers and stabilizing them by preventing depolymerization, which leads to cell cycle arrest and apoptosis. Capecitabine is a prodrug that is enzymatically converted to 5-fluorouracil (5-FU) within the body, where it inhibits thymidylate synthase and interferes with DNA synthesis and RNA processing. This specific combination was evaluated in the ICE II (GBG 52) trial to determine its efficacy and safety compared to standard chemotherapy (EC or CMF) in non-frail patients aged 65 years or older with moderate to high-risk primary breast cancer.
- Other names
- nab-paclitaxel plus capecitabineICE II regimen
02
Targets
TS (Thymidylate synthase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on capecitabine + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capecitabine + nab-paclitaxel.